66 results about "Colorectal adenoma" patented technology

Methods of identifying subjects at increased risk of cancer, based upon detection of biofilms and/or biofilm-associated microbes within a subject, are disclosed. Therapies designed to prevent formation and/or reduce the size of biofilms in a subject identified to be at increased risk of cancer based upon detection of biofilms and/or biofilm-associated microbes are disclosed. In particular embodiments, the invention provides for identification of a subject at elevated risk of developing or having colorectal cancer and/or a colorectal adenoma, based upon detection of a biofilm and/or biofilm-associated bacteria within the gastrointestinal tract of the subject (optionally, within a biopsy specimen and/or stool sample of such subject). Therapies involving administration of an antibiotic agent and/or a probiotic agent to a subject, to prevent or reduce biofilm formation within the gastrointestinal tract of the subject, optionally provided in combination with additional cancer therapy, are also disclosed.

Disclosed is a method for determining the presence or absence of a colorectal tumor, specifically colorectal cancer or colorectal adenoma, with high sensitivity and high specificity by employing the methylation of DNA as a measure. Also disclosed is a kit for carrying out the method. Specifically, measurement is made on the degree of methylation of one or more CpG sequences contained in the region lying between positions -477 to -747, more preferably a CGCG sequence contained in the region lying between positions -688 to -691, in TWIST1 gene (Homo sapiens twist homolog 1; Drosophila gene) located on the genome sequence of a test cell.

The present disclosure relates to methods and compositions to ameliorate or treat at least one symptom of colorectal cancer and/or adenomatous polyposis coli (APC). For example, some embodiments of the methods and compositions may reduce recurrence of colorectal adenomas and/or extend the life of a subject having colorectal cancer and/or APC. Some embodiments of the disclosure include maintaining a the total body weight in a subject having colorectal cancer and/or APC. According to some embodiments, a method of the disclosure may include administering a bile acid composition to a subject. A bile acid composition may include, in some embodiments, an aqueous solution that is free or substantially free of precipitates or particles. A aqueous solution may include (1) a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and/or 7-ketolithocholic acid, (2) a carbohydrate, and (3) water. An aqueous composition may further include an alkali.

The present invention relates to the differential expression of genes in colorectal adenoma and adenocarcinoma cells and their correlation with chromosomal aberrations. The present invention provides tools for detecting chromosomal aberrations linked to progression of adenomas into adenocarcinoma cells. The present invention discloses methods and tools for in vivo and in vitro diagnosis of colorectal tumours.

The invention discloses a kit for distinguishing colorectal adenomas from colorectal cancer. The kit for distinguishing or assisting in distinguishing the colorectal adenomas from the colorectal cancer comprises a device for detecting phospholipids content and a contrast card established by the phospholipids content, wherein phospholipids are sphingosylphosphorylcholine (SPC), 16:0 sphingomyelin (SM), 18:0SM, 14:0 lysophosphatidylcholine (LPC), 16:0LPC, 18:0LPC, 20:0LPC and 22:0LPC. Saturated LPC, SPC and SM are taken as markers, and a molecular model for distinguishing the colorectal adenomas from the colorectal cancer is established, and has colorectal cancer distinguishing sensitivity of 90 percent and colorectal cancer distinguishing specificity of 93 percent.

The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. The present inventors discovered that there are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore the inventors applied the discovery to diagnosis and found that colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No. 09961D, Distributor: Becton Dickinson), reacting with GlcNAc-6-sulfated sugar residues, which are produced specifically by the enzyme present in colorectal cancer and colorectal adenoma tissues could be used for the examination of colorectal cancers and colorectal adenomas.

A group of diagnostic biomarkers usable for diagnosis of colorectal cancer or colorectal adenoma. A method for detecting colorectal cancer or colorectal adenoma using the group of diagnostic biomarkers is also provided. For example, the method is a non-invasive approach that may utilize serum samples for detecting colorectal cancer. Moreover, the method for detecting colorectal cancer may detect colorectal cancer of different stages (e.g., pre-cancer stage, early stage, middle stage, late stage).

The invention relates to a humanized intestinal cancer precancerous lesion immortalized epithelial cell line and a construction method and application thereof. The construction method comprises the following steps: firstly, transfecting primarily separated human colorectal adenoma polyp epithelial cells by using an SV40 overexpression lentiviral vector, then performing screening by using puromycin, and finally amplifying the screened cells to obtain the humanized intestinal cancer precancerous lesion immortalized epithelial cell line. The humanized intestinal cancer precancerous lesion immortalized epithelial cell line constructed by the invention overcomes the problems that conventional adenoma polyp cannot be subjected to passage in vitro, is low in cell proliferation and poor in cell activity, and cannot meet the cell passage requirement. According to the invention, the humanized intestinal cancer precancerous lesion immortalized epithelial cell line is established for the first time, an important cell experiment tool is provided for developing an in-vitro experiment of intestinal cancer precancerous lesions, and preclinical researches such as new drug screening and drug effectcomponents are also convenient to develop.

The present disclosure provides fecal microbial markers for diagnosing colorectal cancer and colorectal adenoma. The present disclosure also provides methods for diagnosing colorectal cancer and colorectal adenoma using these intestinal microbial markers.

This invention provides minimally invasive methods, reagents, diagnostic and prognostic markers useful for staging, prognosis and surveillance of colorectal cancers, and therapeutic intervention in individuals with colorectal cancers, or individuals who may be susceptible to developing colorectal cancers.

The invention provides a lipid molecule combination used as a biomarker. The lipid molecule combination is prepared into a kit, human blood is used as the sample, the content of lipid marking molecules selected in the kit is tested and analyzed comprehensively, and the possibility of colorectal adenomas of the tested unit is determined according to the analysis result so that colorectal adenomas is detected early and a patient is diagnosed and treated in time.

The invention discloses a kit for screening colorectal adenomas (CRA). The kit for screening or screening CRA in an aided manner comprises a device for detecting the contents of phospholipids and a comparison card established by the contents of phospholipids, wherein the phospholipids include 16:0SM, 18:0SM, 14:0LPC, 16:0LPC, 18:2LPC, 18:1LPC, 18:0LPC, 20:4LPC, 20:0LPC, 22:6LPC and 22:0LPC. A molecular model for distinguishing healthy controls from CRA patients is established by taking saturated LPC, 20:4LPC and SM as markers, and the sensitivity and specificity of the model in distinguishing the CRA are respectively 89% and 80%.

The invention discloses a pharmaceutical composition containing medicinal calcium salt for early preventing colorectal adenoma or colorectal cancer. The pharmaceutical composition contains sodium butyrate and medicinal calcium salt, wherein the mass ratio of the sodium butyrate to elemental calcium in the pharmaceutical composition is (2.47-4.95):1. The pharmaceutical composition disclosed by the invention can reduce cancer genes related to the colorectal cancer and can increase related cancer suppressor genes and signal passages to suppress colorectal cancer cell proliferation and migration capabilities and retard cell growth cycle, thereby achieving the purposes of suppressing the occurrence of the colorectal cancer, lowering the incidence rate of the colorectal cancer of mice, and reducing the tumor volume.

The invention relates to the field of biological detection, in particular to molecular detection of organisms, more particularly to a group of exosome RNA markers associated with colorectal adenoma and an application thereof.

The invention discloses a plasma marker combination for early diagnosis or prognosis prediction of colorectal cancer. Specifically, the present invention obtains miRNA which is obviously abnormally expressed in colorectal cancer plasma, namely miR-224-5p, miR-301a-3p, miR-145-5p, miR-193b-3p and miR-1183. The invention finds that the plasma miRNA combination can be used as a marker for early diagnosis or prognosis judgment of colorectal cancer by researching the expression difference of the plasma miRNA in patients with colorectal cancer and colorectal adenoma at various stages and healthy people.

The present invention provides a method for detecting ACF by analyzing a test region of large intestine tissue at the molecular level. Namely, the present invention relates to a method for detecting aberrant crypt foci (ACF) that comprises detecting an ACF detection marker in a test region of large intestine tissue, by using one or more types of molecules for which ACF-specific expression increases as the ACF detection marker, the molecule being selected from the group consisting of SLC2a1, and SLC7a7; an ACF detection marker for detecting the ACF in human-derived large intestine tissue, that is SLC2a1, or SLC7a7; and, a method for evaluating risk of colorectal cancer and colorectal adenoma in subjects based on the results of detecting ACF in a test region of large intestine tissue of the subjects using the aforementioned ACF detection method.

The invention discloses novel application of a DNA binding site CTCF_55 of a multifunctional transcriptional regulation factor CTCF, and particularly relates to application of the DNA binding site CTCF_55 in preparation of a kit for early diagnosis of a colorectal tumor. The nucleotide of the binding site is shown as SEQ ID NO: 1. The accuracy of the CTCF binding site provided by the invention for detecting colorectal adenomas or a colorectal cancer is obviously higher than that of a reported DNA methylated molecular marker; furthermore, the DNA binding site of the CTCF may be a biological marker for monitoring the tumor treatment effect, estimating the prognosis effect and tumor molecular parting (such as CIMP parting). In conclusion, the invention provides a new idea for searching a more effective molecular marker for early diagnosis of the tumor, monitoring of the treatment effect, estimation of the prognosis effect and the molecular parting, and the application has important significance for prevention and treatment of the tumor.

The present invention refers to an in vitro method for identifying patients at risk of suffering from colorectal cancer and/or colorectal adenomas, preferably advanced colorectal adenomas, based on measuring the expression profile or level of some miRNAs, e.g. miR-15b, which are up-regulated or over-expressed in patients suffering from said diseases.

The invention discloses a novel use of a DNA (deoxyribonucleic acid) binding site CTCF_13 of a multifunctional transcription regulation factor CTCF, i.e. application thereof to preparation of a kit for early diagnosis of colorectal neoplasms. The nucleotide sequence of the binding site is shown as SEQ ID NO:1. The accuracy of the binding site CTCF, provided by the invention, in detection of either colorectal adenomas or the colorectal neoplasms is remarkably higher than that of a reported DNA methylated molecular marker; moreover, the DNA binding site of the CTCF is also likely to become a biomarker for tumor treatment effect monitoring, prognosis effect evaluation and tumor molecular typing (such as CIMP typing). In brief, a novel concept is provided for seeking for a more effective molecular marker for early diagnosis of tumors, treatment effect monitoring, prognosis effect evaluation and molecular typing, and is significant for tumor prevention and treatment.